Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration

NCT06116890 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular Age-Related Macular Degeneration (nAMD)

Interventions

DRUG: KHK4951
DRUG: Aflibercept Injection

Sponsor

Kyowa Kirin Co., Ltd.